ACAD Stock Overview
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases.
No risks detected for ACAD from our risk checks.
ACADIA Pharmaceuticals Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$23.29|
|52 Week High||US$33.99|
|52 Week Low||US$13.73|
|1 Month Change||-18.57%|
|3 Month Change||-3.84%|
|1 Year Change||43.06%|
|3 Year Change||-42.11%|
|5 Year Change||12.03%|
|Change since IPO||247.61%|
Recent News & Updates
Insufficient Growth At ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Hampers Share PriceMay 22
Acadia Pharmaceuticals: Nuplazid's (Pimavanserin) Last HurrahOct 19
FDA accepts Acadia's new drug application for Rett syndrome treatment trofinetideSep 12
Acadia: Powerful Unfolding CatalystsAug 03
Acadia Pharma submits marketing application to FDA for trofinetide to treat Rett syndromeJul 18
FDA AdComm Rejects Nuplazid This Time But Acadia's Race Isn't Run YetJun 29
Companies Like ACADIA Pharmaceuticals (NASDAQ:ACAD) Can Afford To Invest In GrowthMay 07
Acadia: Catalysts StackingApr 28
Acadia's NUPLAZID, FDA's Second Chance To Get Alzheimer's RightFeb 22
Acadia: Big News On The Near HorizonDec 08
Acadia Pharmaceuticals: Refunding A Former ChampionSep 29
Acadia's Essential Questions Heading Into Q2 2021 EarningsJul 30
Here's Why We Think ACADIA Pharmaceuticals Inc.'s (NASDAQ:ACAD) CEO Compensation Looks Fair for the time beingJun 16
Acadia's Big RevealMay 10
Acadia maintains 2021 sales guidance as Q1 net sales rise 18%May 05
|ACAD||US Biotechs||US Market|
Return vs Industry: ACAD exceeded the US Biotechs industry which returned 11.8% over the past year.
Return vs Market: ACAD exceeded the US Market which returned 16.8% over the past year.
|ACAD Average Weekly Movement||8.4%|
|Biotechs Industry Average Movement||9.1%|
|Market Average Movement||5.5%|
|10% most volatile stocks in US Market||14.2%|
|10% least volatile stocks in US Market||2.5%|
Stable Share Price: ACAD is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: ACAD's weekly volatility (8%) has been stable over the past year.
About the Company
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The company also develops Trofinetide, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome; Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-204 for the treatment of Alzheimer’s disease psychosis; antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms.
ACADIA Pharmaceuticals Inc. Fundamentals Summary
|ACAD fundamental statistics|
Is ACAD overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ACAD income statement (TTM)|
|Cost of Revenue||US$298.66m|
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
|Earnings per share (EPS)||-0.68|
|Net Profit Margin||-20.12%|
How did ACAD perform over the long term?See historical performance and comparison